Huya Bioscience International LLC, of San Diego, appointed Akira Miyazato vice president, head of clinical research and development in Japan. His role is to support the company’s advancement of its lead anti-cancer drug HBI-8000 through accelerated development in Japan for lymphoma. Read More

TOKYO – Japan has made great strides in speeding drug and device approvals, but there are concerns that fewer products are coming to market despite the visible regulatory improvements over the past decade. Read More

HONG KONG – South Korea’s Gtreebnt Co. Ltd., a firm that started out researching and developing software, is expanding its drug pipeline, most recently through a deal with a U.S. medical research foundation to develop a product for a lethal form of brain cancer. Read More

HONG KONG – Hormones released during chronic stress have been shown to remodel the lymphatic vasculature to promote cancer cell dissemination in mice, while targeting that stress pathway with beta-blockers may prove useful in blocking the spread of cancer cells, Australian scientists report in the March 1, 2016, issue of Nature Communications. Read More

HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company. Read More

HONG KONG – China’s Wuxi Biologics Co. Ltd. managed a breakthrough by getting a biological product it manufactures approved in the use of clinical trials in Belgium, making it the first-ever China-made biologic dosed in a clinical trial in the European Union (EU). Read More